Mississauga, Canada
CanVeer Biopharma Inc. (the “Company” or “CanVeer”), a preclinical biopharmaceutical company developing therapies for severe respiratory diseases with high unmet medical need, is pleased to announce the filing of its international Patent Cooperation Treaty (PCT) patent application of its investigational new drug candidate AlveoShield™, marking an important milestone in strengthening the Company’s global intellectual property strategy for chronic respiratory conditions
The patent application, titled “METHODS AND COMPOSITIONS FOR PREVENTING, ATTENUATING OR TREATING LUNG DISEASES AND/OR INJURY,” builds upon CanVeer’s previously filed United States provisional patent and supports the continued development of the Company’s proprietary therapeutic platform, including its lead investigational program, AlveoShield™.
The PCT application was formally submitted through the Canadian Intellectual Property Office acting as the Canadian Receiving Office. The filing establishes an international priority date and provides a strategic framework for pursuing patent protection across more than 150 participating jurisdictions worldwide, supporting CanVeer’s long-term commercialization and partnering strategy. The intellectual property underlying the application is owned by CanVeer.
CanVeer’s lead therapeutic candidate, AlveoShield™, is currently being developed as a potential first-in-class disease modifying therapy for bronchopulmonary dysplasia (BPD), a severe respiratory condition affecting preterm newborns who require oxygen support at birth to survive. Currently there are no approved disease-modifying therapies for BPD in the clinic, putting over 150,000 preterm newborns annually in North America at risk of developing BPD, and suffering lifelong severe respiratory consequences.
CanVeer is also evaluating formulation and pulmonary delivery strategies to support future clinical translation and commercialization of AlveoShield™.
While the Company’s initial development focus is neonatal respiratory disease, the broader patent strategy strengthens potential future applications in additional respiratory conditions involving lung injury and inflammation.
IPON Support Strengthens Global IP Strategy
CanVeer was previously accepted into the Intellectual Property Ontario (IPON) program, which enables Ontario companies advancing intellectual property protection and commercialization strategies. Under the program, CanVeer is eligible to receive up to CAD $300,000 in lifetime support, operating under an 80% provincial cost-sharing model for eligible intellectual property activities.
The support is positioned to help offset costs associated with international patent prosecution, freedom-to-operate analyses, competitive IP landscaping, and commercialization-related legal activities.
Management Commentary
“The filing of our international PCT application represents an important milestone in CanVeer’s commercial strategy as we continue advancing AlveoShield™ towards the clinic,” said Sherif Louis, CEO of CanVeer. “Establishing international priority rights empowers our long-term objective of protecting the program and assures global market potential and exclusivity.”
“Support from IPON has played an important role in accelerating the development of our global intellectual property strategy,” said Behzad Yeganeh, CSO of CanVeer and co-inventor of the technology. “Combined with the guidance of our IP Counsel, SMART & BIGGAR, this PCT filing further strengthens the patent foundation supporting the future clinical and commercial development of AlveoShield™ and our broader respiratory therapeutic platform.”
About CanVeer Biopharma Inc.
CanVeer Biopharma is a privately owned pre-clinical biopharmaceutical company advancing innovative therapeutics for chronic diseases with high unmet medical needs. The Company’s lead program, AlveoShield™, is being developed as a potential therapy for bronchopulmonary dysplasia (BPD), a severe chronic respiratory condition affecting preterm infants who require assisted ventilation at birth. Currently, there are no approved disease-modifying therapies for BPD. AlveoShield™ is designed to target biological pathways underlying lung injury to support normal lung development. For more information, please visit www.canveer.com.
For further information, please contact:
Sherif Louis
Chief Executive Officer
CanVeer Biopharma Inc.
647-293-6555
[email protected]
www.canveer.com
Cautionary Note Regarding Forward-Looking Statements
This news release contains “forward-looking information” within the meaning of applicable Canadian securities laws. Forward-looking information is often identified by terms such as “will,” “intends,” “potential,” “aiming,” “planned,” or similar expressions and includes statements regarding the clinical efficacy and commercial viability of AlveoShield™, anticipated development and IP filing timelines, regulatory milestones, and the benefits of the IPON program. These statements are based on current expectations and are subject to significant risks, uncertainties, and assumptions that could cause actual results to differ materially. These include risks inherent in drug development, regulatory processes, intellectual property prosecution, and the availability of program funding. Readers are cautioned not to place undue reliance on forward-looking information. The Company undertakes no obligation to update forward-looking statements except as required by law. This release is for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy any securities of CanVeer Biopharma Inc.
